Senescence in chronic allograft nephropathy

被引:13
|
作者
Pena, Maria del Pilar Sosa [1 ,2 ]
Lopez-Soler, Reynold [3 ]
Melendez, J. Andres [1 ,2 ]
机构
[1] SUNY Polytech Inst, Coll Nanoscale Sci, 257 Fuller Rd,NFE 4313, Albany, NY 12203 USA
[2] SUNY Polytech Inst, Coll Engn, 257 Fuller Rd,NFE 4313, Albany, NY 12203 USA
[3] Albany Med Ctr, Dept Surg, Div Transplantat, Albany, NY USA
关键词
fibrosis; kidney transplant; transplant rejection; EPITHELIAL-MESENCHYMAL TRANSITION; AGE-DEPENDENT RESPONSES; CHRONIC KIDNEY-DISEASE; CELLULAR SENESCENCE; OXIDATIVE STRESS; RENAL-ALLOGRAFTS; SECRETORY PHENOTYPE; MATRIX METALLOPROTEINASES; INTERSTITIAL FIBROSIS; PROTOCOL BIOPSIES;
D O I
10.1152/ajprenal.00195.2016
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Despite increasing numbers of patients on dialysis, the numbers of renal transplants performed yearly have remained relatively static. During the last 50 years, there have been many advances in the pharmacology of prevention of organ rejection. However, most patients will suffer from a slow but steady decline in renal function leading to graft loss. The most common cause of long-term graft loss is chronic allograft nephropathy (CAN). Therefore, elucidating and understanding the mechanisms involved in CAN is crucial for achieving better posttransplant outcomes. It is thought that the development of epithelial to mesenchymal transition (EMT) in proximal tubules is one of the first steps towards CAN, and has been shown to be a result of cellular senescence. Cells undergoing senescence acquire a senescence associated secretory phenotype (SASP) leading to the production of interleukin-1 alpha (IL-1 alpha), which has been implicated in several degenerative and inflammatory processes including renal disease. A central mediator in SASP activation is the production of reactive oxygen species (ROS), which are produced in response to numerous physiological and pathological stimuli. This review explores the connection between SASP and the development of EMT/CAN in an effort to suggest future directions for research leading to improved long-term graft outcomes.
引用
收藏
页码:F880 / F889
页数:10
相关论文
共 50 条
  • [21] Sirolimus therapy in chronic allograft nephropathy
    Chaaban, AM
    Elfurayh, OIBR
    Nadri, QJAW
    Hamasni, IM
    Elimad, ZR
    Korbi, LM
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 : V162 - V162
  • [22] Chronic Allograft Nephropathy - an Indian Study
    Sharma, D.
    [J]. TRANSPLANTATION, 2012, 94 (10) : 118 - 118
  • [23] Predictive factors in chronic allograft nephropathy
    Scolari, MP
    Cappuccilli, ML
    Lanci, N
    La Manna, G
    Comai, G
    Persici, E
    Todeschini, P
    Faenza, A
    Stefoni, S
    [J]. TRANSPLANTATION PROCEEDINGS, 2005, 37 (06) : 2482 - 2484
  • [24] The pathogenesis and treatment of chronic allograft nephropathy
    Li, Can
    Yang, Chul Woo
    [J]. NATURE REVIEWS NEPHROLOGY, 2009, 5 (09) : 513 - 519
  • [25] Oxidative stress and chronic allograft nephropathy
    Ha, H
    Park, J
    Kim, YS
    Endou, H
    [J]. YONSEI MEDICAL JOURNAL, 2004, 45 (06) : 1049 - 1052
  • [26] Minimizing the Risk of Chronic Allograft Nephropathy
    Weir, Matthew R.
    Wali, Ravinder K.
    [J]. TRANSPLANTATION, 2009, 87 (08) : S14 - S18
  • [27] The pathogenesis and treatment of chronic allograft nephropathy
    Can Li
    Chul Woo Yang
    [J]. Nature Reviews Nephrology, 2009, 5 : 513 - 519
  • [28] Proteome analysis in chronic allograft nephropathy
    Kreusser, Stefanie
    Vollenbroeker, Beate
    Henning, Stefanie
    Reinhardt, Christian
    Amann, Kerstin
    Peter-Katalinic, Jasna
    Pavenstaedt, Hermann
    Gabriels, Gert
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 : 206 - 206
  • [29] A predictive model for chronic allograft nephropathy
    Cardinal, H
    Madore, F
    St-Louis, G
    Hébert, MJ
    [J]. TRANSPLANTATION PROCEEDINGS, 2002, 34 (05) : 1810 - 1811
  • [30] Correlation of chronic allograft nephropathy and dyslipidemia
    Valavi, E.
    Otookesh, H.
    [J]. PEDIATRIC NEPHROLOGY, 2007, 22 (09) : 1565 - 1565